Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2025-12-29 @ 8:11 AM
Study NCT ID:
NCT01646203
Status:
COMPLETED
Last Update Posted:
2019-01-18
First Post:
2012-06-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of IMC-TR1 in Participants With Advanced Solid Tumors
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to evaluate the safety and tolerability of anti-TGFβRII monoclonal antibody (IMC-TR1) in participants with advanced solid tumors, as well as gather evidence of anti-tumor activity.
Detailed Description:
This is the first-in-human Phase 1 study of IMC-TR1.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| I5I-IE-JTCA | OTHER | Eli Lilly and Company | View |